Therefore, anti‐VCAM‐1 targeted ultrasound contrast agents can achieve ultrasound molecular imaging of AKI to show changes in renal microcirculatory perfusion and inflammatory responses. This evidence concerns the gene VCAM1 and acute kidney injury.